Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TR study of DS-8201a for HER2-amplified solid tumors identified by ctDNA analysis
jRCT1080224684Completed
- Sponsor
- National Cancer Center Hospital East
- Start
- May 2019
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of trastuzumab deruxtecan in Nonhematologic neoplasms, sponsored by National Cancer Center Hospital East. Started May 2019; status: completed.
02
Drugs
trastuzumab deruxtecan
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT1080224684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080224684.